Silo Pharma, Inc. SILO

Company Overview

Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems for underserved neurological, psychiatric, and pain-related conditions. The company operates within the biotechnology and specialty pharmaceutical industries, with research programs involving ketamine-based therapies, psychedelic-derived compounds, and targeted central nervous system (CNS) applications. Its primary business model centers on advancing intellectual property, licensing agreements, sponsored research partnerships, and preclinical or early-stage clinical development programs.

The company has historically emphasized collaborations with academic institutions and contract research organizations to support formulation development and translational research. Silo Pharma’s positioning has been tied to emerging interest in psychedelic-assisted therapeutics and intranasal or controlled-release drug delivery technologies. Public filings and company disclosures indicate that its strategy evolved from broader biotechnology licensing activity into a more concentrated CNS and psychedelic therapeutics focus, particularly following increased industry investment in neuropsychiatric treatment innovation.